First clinical experience with a dedicated PET for hanging breast molecular imaging

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 57, Issue 1, 2013, Pages 92-100

  Koolen, B B ^a   Aukema, T S ^a   Gonzalez Martinez A J ^b   Vogel, W V ^a   Caballero Ontanaya, L ^b   Vrancken Peeters, M J T F D ^a   Vroonland, C J J ^a   Rutgers, E J T H ^a   Benlloch Baviera, J M ^c   Valdes Olmos R A ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b ONCOVISION (GEM Imaging SA)   (Spain)

^c UNIVERSITAT POLITÈCNICA DE VALÈNCIA   (Spain)

Author keywords

Breast cancer; Breast neoplasm; Breast PET; Dedicated PET; PET CT; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BODY POSTURE; BREAST; BREAST CANCER; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER SIZE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEASIBILITY STUDY; FEMALE; HANGING BREAST MOLECULAR IMAGING; HUMAN; INTERMETHOD COMPARISON; MEASUREMENT; MOLECULAR IMAGING; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR;

ADULT; AGED; BIOPSY; BREAST NEOPLASMS; EQUIPMENT DESIGN; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAMMOGRAPHY; MIDDLE AGED; MOLECULAR IMAGING; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84876575088     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. van der Hoeven JJM, Krak NC, Hoekstra OS, Comans EFI, Boom RPA, van Geldere D et al. 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol 2004;22:1253-9. (Pubitemid 41079839)
2. Fuster D, Duch J, Paredes P, Velasco M, Muñoz M, Santamaría G et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol.2008;26:4746-51.
3. Heusner TA, Kuemmel S, Umutlu L, Koeninger A, Freudenberg LS, Hauth EAM et al. Breast cancer staging in a single session: whole-body PET/CT mammography. J Nucl Med 2008;49:1215-22.
4. Morris PG, Lynch C, Feeney JN, Patil S, Howard J, Larson SM et al. Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer. J Clin Oncol 2010;28:3154-9.
5. Hodgson NC, Gulenchyn KY. Is there a role for positron emission tomography in breast cancer staging? J Clin Oncol 2008;26:712-20. (Pubitemid 351264383)
6. Niikura N, Ueno NT. The Role of F-FDG-Positron Emission Tomography/Computed Tomography in Staging Primary Breast Cancer. J Cancer 2010;1:51-3.
7. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008;49:480-508. (Pubitemid 351355215)
8. Veronesi U, De Cicco C, Galimberti VE, Fernandez JR, Rotmensz N, Viale G et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 2007;18:473-8. (Pubitemid 46359625)
9. Straver ME, Aukema TS, Olmos RAV, Rutgers EJT, Gilhuijs KGA, Schot ME et al. Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients. Eur J Nucl Med Mol Imaging 2010;37:1069-76.
10. Aukema TS, Straver ME, Peeters MJTFDV, Russell NS, Gilhuijs KGA, Vogel WV et al. Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer. Eur J Cancer 2010;46:3205-10.
11. Mahner S, Schirrmacher S, Brenner W, Jenicke L, Habermann CR, Avril N et al. Comparison between positron emission tomography using 2-[fluorine-18]fluoro- 2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol 2008;19:1249-54. (Pubitemid 351911953)
12. Aukema TS, Rutgers EJT, Vogel WV, Teertstra HJ, Oldenburg HS, Vrancken Peeters MTFD et al. The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques. Eur J Surg Oncol 2010;36:387-92.
13. Avril N, Rosé CA, Schelling M, Dose J, Kuhn W, Bense S et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000;18:3495-502.
14. Vidal-Sicart S, Aukema TS, Vogel WV, Hoefnagel CA, Valdes Olmos RA. [Added value of prone position technique for PET-TAC in breast cancer patients]. Rev Esp Med Nucl 2010;29:230-5.
15. Berg WA, Weinberg IN, Narayanan D, Lobrano ME, Ross E, Amodei L et al. High-resolution fluorodeoxyglucose positron emission tomography with compression ("positron emission mammography") is highly accurate in depicting primary breast cancer. Breast J 2006;12:309-23. (Pubitemid 43989975)
16. Berg WA, Madsen KS, Schilling K, Tartar M, Pisano ED, Larsen LH et al. Breast cancer: comparative effectiveness of positron emission mammography and MR imaging in presurgical planning for the ipsilateral breast. Radiology 2011;258:59-72.
17. Murthy K, Aznar M, Thompson CJ, Loutfi A, Lisbona R, Gagnon JH. Results of preliminary clinical trials of the positron emission mammography system PEM-I: a dedicated breast imaging system producing glucose metabolic images using FDG. J Nucl Med 2000;41:1851-8.
18. Schilling K, Narayanan D, Kalinyak JE, The J, Velasquez MV, Kahn S et al. Positron emission mammography in breast cancer presurgical planning: comparisons with magnetic resonance imaging. Eur J Nucl Med Mol Imaging 2011;38:23-36.
19. Loo CE, Straver ME, Rodenhuis S, Muller SH, Wesseling J, Vrancken Peeters M-JTFD et al. Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol 2011;29:660-6.
20. MacDonald L, Edwards J, Lewellen T, Haseley D, Rogers J, Kinahan P. Clinical imaging characteristics of the positron emission mammography camera: PEM Flex Solo II. J Nucl Med 2009;50:1666-75.
21. Crippa F, Seregni E, Agresti R, Chiesa C, Pascali C, Bogni A et al. Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med 1998;25:1429-34. (Pubitemid 28464119)
22. Avril N, Menzel M, Dose J, Schelling M, Weber W, Jänicke F et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001;42:9-16. (Pubitemid 32104770)
23. Gil-Rendo A, Martínez-Regueira F, Zornoza G, García-Velloso MJ, Beorlegui C, Rodriguez-Spiteri N. Association between [18F] fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg 2009;96:166-70.
24. Groheux D, Giacchetti S, Moretti J-L, Porcher R, Espié M, Lehmann-Che J et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging 2011;38:426-35.
25. McDermott GM, Welch A, Staff RT, Gilbert FJ, Schweiger L, Semple SIK et al. Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat 2007;102:75-84. (Pubitemid 46294965)
26. Avril N, Sassen S, Roylance R. Response to therapy in breast cancer. J Nucl Med 2009;50(Suppl 1):55S-63S.
27. Duch J, Fuster D, Muñoz M, Fernández PL, Paredes P, Fontanillas M et al. 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging 2009;36:1551-7.
28. Kumar A, Kumar R, Seenu V, Gupta SD, Chawla M, Malhotra A et al. The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Eur Radiol 2009;19:1347-57.
29. Schwarz-Dose J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol 2009;27:535-41.
30. Quarles van Ufford HME, van Tinteren H, Stroobants SG, Riphagen II, Hoekstra OS. Added value of baseline 18F-FDG uptake in serial 18F-FDG PET for evaluation of response of solid extracerebral tumors to systemic cytotoxic neoadjuvant treatment: a meta-analysis. J Nucl Med 2010;51:1507-16.
31. Soriano A, González A, Orero A, Moliner L, Carles M, Sánchez F et al. Attenuation correction without transmission scan for the MAMMI breast PET. Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment 2011;648:S75-S8.
32. Stahl AR, Heusner TA, Hartung V, Nagarajah J, Bockisch A, Hahn S et al. Time course of tumor SUV in 18F-FDG PET of breast cancer: presentation of a simple model using a single reference point for time corrections of tumor SUVs. J Nucl Med 2011;52:18-23.
33. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med 2007;48:932-45. (Pubitemid 46909922)
34. Werner MK, Aschoff P, Reimold M, Pfannenberg C. FDG-PET/CT-guided biopsy of bone metastases sets a new course in patient management after extensive imaging and multiple futile biopsies. Br J Radiol 2011;84:e65-7.
35. Klaeser B, Mueller MD, Schmid RA, Guevara C, Krause T, Wiskirchen J. PET-CT-guided interventions in the management of FDG-positive lesions in patients suffering from solid malignancies: initial experiences. Eur Radiol 2009;19:1780-5.